LIVIVO - Suchergebnisse -

Suchergebnis

Treffer 1 - 9 von insgesamt 9

Suchoptionen

Artikel: Integrating copy number data of 64 iAMP21 BCP-ALL patients narrows the common region of amplification to 1.57 Mb.

Hormann, Femke M / Hoogkamer, Alex Q / Boeree, Aurélie / Sonneveld, Edwin / Escherich, Gabriele / den Boer, Monique L / Boer, Judith M

Frontiers in oncology

2023 Band 13, Seite(n) 1128560

Abstract: Background and purpose: Intrachromosomal amplification of chromosome 21 (iAMP21) is a rare subtype of B-cell precursor acute lymphoblastic leukaemia (BCP-ALL). It is unknown how iAMP21 contributes to leukaemia. The currently known commonly amplified ... ...

Abstract	Background and purpose: Intrachromosomal amplification of chromosome 21 (iAMP21) is a rare subtype of B-cell precursor acute lymphoblastic leukaemia (BCP-ALL). It is unknown how iAMP21 contributes to leukaemia. The currently known commonly amplified region is 5.1 Mb. Methods: We aimed to narrow down the common region of amplification by using high resolution techniques. Array comparative genomic hybridization (aCGH) was used to determine copy number aberrations, Affymetrix U133 Plus2 expression arrays were used to determine gene expression. Genome-wide expression correlations were evaluated using Globaltest. Results: We narrowed down the common region of amplification by combining copy number data from 12 iAMP21 cases with 52 cases from literature. The combined common region of amplification was 1.57 Mb, located from 36.07 to 37.64 Mb (GRCh38). This region is located telomeric from, but not including, Discussion: The more precise definition of the common region of amplification could be beneficial in the diagnosis of iAMP21 based on copy number analysis from DNA sequencing or arrays as well as stimulate functional research into the role of the included genes in iAMP21 biology.
Sprache	Englisch
Erscheinungsdatum	2023-02-23
Erscheinungsland	Switzerland
Dokumenttyp	Journal Article
ZDB-ID	2649216-7
ISSN	2234-943X
ISSN	2234-943X
DOI	10.3389/fonc.2023.1128560
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: Tyrosine kinase inhibitor resistance in de novo BCR::ABL1-positive BCP-ALL beyond kinase domain mutations.

van Outersterp, Inge / Boer, Judith M / van de Ven, Cesca / Reichert, Caitlin E J / Boeree, Aurelie / Kruisinga, Brian / de Groot-Kruseman, Hester A / Escherich, Gabriele / Sijs-Szabo, Aniko / Rijneveld, Anita W / den Boer, Monique L

Blood advances

2024 Band 8, Heft 8, Seite(n) 1835–1845

Abstract: Abstract: A better understanding of ABL1 kinase domain mutation-independent causes of tyrosine kinase inhibitor (TKI) resistance is needed for BCR::ABL1-positive B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Although TKIs have dramatically ... ...

Abstract	Abstract: A better understanding of ABL1 kinase domain mutation-independent causes of tyrosine kinase inhibitor (TKI) resistance is needed for BCR::ABL1-positive B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Although TKIs have dramatically improved outcomes, a subset of patients still experiences relapsed or refractory disease. We aimed to identify potential biomarkers of intrinsic TKI resistance at diagnosis in samples from 32 pediatric and 19 adult patients with BCR::ABL1-positive BCP-ALL. Reduced ex vivo imatinib sensitivity was observed in cells derived from newly diagnosed patients who relapsed after combined TKI and chemotherapy treatment compared with cells derived from patients who remained in continuous complete remission. We observed that ex vivo imatinib resistance was inversely correlated with the amount of (phosphorylated) BCR::ABL1/ABL1 protein present in samples that were taken at diagnosis without prior TKI exposure. This suggests an intrinsic cause of TKI resistance that is independent of functional BCR::ABL1 signaling. Simultaneous deletions of IKZF1 and CDKN2A/B and/or PAX5 (IKZF1plus), as well as deletions of PAX5 alone, were related to ex vivo imatinib resistance. In addition, somatic lesions involving ZEB2, SETD2, SH2B3, and CRLF2 were associated with reduced ex vivo imatinib sensitivity. Our data suggest that the poor prognostic value of IKZF1(plus) deletions is linked to intrinsic mechanisms of TKI resistance other than ABL1 kinase domain mutations in newly diagnosed pediatric and adult BCR::ABL1-positive BCP-ALL.
Mesh-Begriff(e)	Adult ; Humans ; Child ; Imatinib Mesylate/pharmacology ; Imatinib Mesylate/therapeutic use ; Fusion Proteins, bcr-abl/metabolism ; Tyrosine Kinase Inhibitors ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Mutation ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/diagnosis ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/genetics
Chemische Substanzen	Imatinib Mesylate (8A1O1M485B) ; Fusion Proteins, bcr-abl (EC 2.7.10.2) ; Tyrosine Kinase Inhibitors ; Protein Kinase Inhibitors
Sprache	Englisch
Erscheinungsdatum	2024-02-21
Erscheinungsland	United States
Dokumenttyp	Journal Article
ZDB-ID	2915908-8
ISSN	2473-9537 ; 2473-9529
ISSN (online)	2473-9537
ISSN	2473-9529
DOI	10.1182/bloodadvances.2023012162
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 7153: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾
- Im ZB MED-Bestand
- Kostenpflichtig bestellen

Artikel: Ibrutinib is not an effective drug in primografts of TCF3-PBX1.

van de Ven, Cesca / Boeree, Aurélie / Stalpers, Femke / Zwaan, C Michel / Den Boer, Monique L

Translational oncology

2020 Band 13, Heft 10, Seite(n) 100817

Abstract: Aim: The Bruton's tyrosine kinase (BTK) inhibitor Ibrutinib (PCI-32765) is effective in patients with multiple myeloma, non-Hodgkin lymphoma and chronic lymphoblastic leukemia. We previously showed that primary cells of children with TCF3-PBX1 positive ... ...

Abstract	Aim: The Bruton's tyrosine kinase (BTK) inhibitor Ibrutinib (PCI-32765) is effective in patients with multiple myeloma, non-Hodgkin lymphoma and chronic lymphoblastic leukemia. We previously showed that primary cells of children with TCF3-PBX1 positive B-cell precursor acute lymphoblastic leukemia (BCP-ALL) express BTK and are sensitive to ibrutinib in vitro. However, preclinical studies in mice are lacking that justify clinical implementation. Methods: Immunocompromised NSG mice were engrafted with a luciferase-positive TCF3-PBX1 leukemic cell line or primary leukemic cells and treated with ibrutinib or placebo. Additionally, primary cells were exposed in vitro to 4 main induction drugs as monotherapy and in combination with ibrutinib. Results: Treatment with ibrutinib of mice engrafted with a TCF3-PBX1 cell line, TCF3-PBX1 positive or TCF3-PBX1 negative primary leukemic cells did not result in prolonged life span compared to placebo treated mice. In vitro sensitivity to ibrutinib was unaltered in leukemic cells obtained from engrafted mice compared to the original material. However, ibrutinib treatment did not affect leukemic cell viability and tumor outgrowth, nor could lymphocytosis be detected. Ibrutinib was biologically active, since hCD19 Conclusions: We conclude that ibrutinib is not the precision medicine of choice for TCF3-PBX1 positive BCP-ALL.
Sprache	Englisch
Erscheinungsdatum	2020-06-18
Erscheinungsland	United States
Dokumenttyp	Journal Article
ZDB-ID	2443840-6
ISSN	1936-5233 ; 1936-5233 ; 1944-7124
ISSN (online)	1936-5233
ISSN	1936-5233 ; 1944-7124
DOI	10.1016/j.tranon.2020.100817
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain.

van Outersterp, Inge / Tasian, Sarah K / Reichert, Caitlin E J / Boeree, Aurélie / de Groot-Kruseman, Hester A / Escherich, Gabriele / Boer, Judith M / den Boer, Monique L

Blood

2023 Band 143, Heft 21, Seite(n) 2178–2189

Abstract: Abstract: Acute lymphoblastic leukemia (ALL) with fusions of ABL-class tyrosine kinase genes other than BCR::ABL1 occurs in ∼3% of children with ALL. The tyrosine kinase genes involved in this BCR::ABL1-like (Ph-like) subtype include ABL1, PDGFRB, ABL2, ...

Abstract	Abstract: Acute lymphoblastic leukemia (ALL) with fusions of ABL-class tyrosine kinase genes other than BCR::ABL1 occurs in ∼3% of children with ALL. The tyrosine kinase genes involved in this BCR::ABL1-like (Ph-like) subtype include ABL1, PDGFRB, ABL2, and CSF1R, each of which has up to 10 described partner genes. ABL-class ALL resembles BCR::ABL1-positive ALL with a similar gene expression profile, poor response to chemotherapy, and sensitivity to tyrosine kinase inhibitors (TKIs). There is a lack of comprehensive data regarding TKI sensitivity in the heterogeneous group of ABL-class ALL. We observed variability in TKI sensitivity within and among each ABL-class tyrosine kinase gene subgroup. We showed that ALL samples with fusions for any of the 4 tyrosine kinase genes were relatively sensitive to imatinib. In contrast, the PDGFRB-fused ALL samples were less sensitive to dasatinib and bosutinib. Variation in ex vivo TKI response within the subset of samples with the same ABL-class tyrosine kinase gene was not associated with the ALL immunophenotype, 5' fusion partner, presence or absence of Src-homology-2/3 domains, or deletions of IKZF1, PAX5, or CDKN2A/B. In conclusion, the tyrosine kinase gene involved in ABL-class ALL is the main determinant of TKI sensitivity and relevant for specific TKI selection.
Mesh-Begriff(e)	Humans ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology ; Protein Kinase Inhibitors/therapeutic use ; Protein Kinase Inhibitors/pharmacology ; Child ; Proto-Oncogene Proteins c-abl/genetics ; Proto-Oncogene Proteins c-abl/metabolism ; src Homology Domains ; Adolescent ; Child, Preschool ; Female ; Male ; Imatinib Mesylate/therapeutic use ; Imatinib Mesylate/pharmacology ; Receptor, Platelet-Derived Growth Factor beta/genetics ; Receptor, Platelet-Derived Growth Factor beta/metabolism ; Dasatinib/therapeutic use ; Dasatinib/pharmacology ; Oncogene Proteins, Fusion/genetics ; Tyrosine Kinase Inhibitors
Chemische Substanzen	Protein Kinase Inhibitors ; Proto-Oncogene Proteins c-abl (EC 2.7.10.2) ; ABL1 protein, human (EC 2.7.10.2) ; Imatinib Mesylate (8A1O1M485B) ; Receptor, Platelet-Derived Growth Factor beta (EC 2.7.10.1) ; Dasatinib (RBZ1571X5H) ; Oncogene Proteins, Fusion ; Tyrosine Kinase Inhibitors
Sprache	Englisch
Erscheinungsdatum	2023-11-09
Erscheinungsland	United States
Dokumenttyp	Journal Article
ZDB-ID	80069-7
ISSN	1528-0020 ; 0006-4971
ISSN (online)	1528-0020
ISSN	0006-4971
DOI	10.1182/blood.2023023120
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Uh III Zs.140: Hefte anzeigen			Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 364: Hefte anzeigen

Über subito bestellen

Details ▾
- Im ZB MED-Bestand
- Kostenpflichtig bestellen

Artikel ; Online: Characterization of a novel

Van Outersterp, Inge / Hormann, Femke M / Hoogkamer, Alex Q / Boeree, Aurélie / Van den Broek, Stijn A / Den Boer, Monique L / Boer, Judith M

Haematologica

2023 Band 108, Heft 10, Seite(n) 2859–2864

Mesh-Begriff(e)	Humans ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics ; Transcription Factors ; Cell Line ; Oncogene Proteins, Fusion/genetics ; Oncogene Proteins, Fusion/metabolism ; MEF2 Transcription Factors/genetics ; MEF2 Transcription Factors/metabolism
Chemische Substanzen	Transcription Factors ; Oncogene Proteins, Fusion ; BCL9 protein, human ; MEF2D protein, human ; MEF2 Transcription Factors
Sprache	Englisch
Erscheinungsdatum	2023-10-01
Erscheinungsland	Italy
Dokumenttyp	Letter
ZDB-ID	2333-4
ISSN	1592-8721 ; 0017-6567 ; 0390-6078
ISSN (online)	1592-8721
ISSN	0017-6567 ; 0390-6078
DOI	10.3324/haematol.2022.281712
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Uh III Zs.76: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾
- Im ZB MED-Bestand
- Kostenpflichtig bestellen

Artikel ; Online: Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia.

Steeghs, Elisabeth M P / Boer, Judith M / Hoogkamer, Alex Q / Boeree, Aurélie / de Haas, Valerie / de Groot-Kruseman, Hester A / Horstmann, Martin A / Escherich, Gabriele / Pieters, Rob / den Boer, Monique L

Scientific reports

2019 Band 9, Heft 1, Seite(n) 4634

Abstract: Pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is associated with a high frequency of copy number alterations (CNAs) in IKZF1, EBF1, PAX5, CDKN2A/B, RB1, BTG1, ETV6, and/or the PAR1 region (henceforth: B-cell development genes). We ... ...

Abstract	Pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is associated with a high frequency of copy number alterations (CNAs) in IKZF1, EBF1, PAX5, CDKN2A/B, RB1, BTG1, ETV6, and/or the PAR1 region (henceforth: B-cell development genes). We aimed to gain insight in the association between CNAs in these genes, clinical outcome parameters, and cellular drug resistance. 71% of newly diagnosed pediatric BCP-ALL cases harbored one or more CNAs in these B-cell development genes. The distribution and clinical relevance of these CNAs was highly subtype-dependent. In the DCOG-ALL10 cohort, only loss of IKZF1 associated as single marker with unfavorable outcome parameters and cellular drug resistance. Prednisolone resistance was observed in IKZF1-deleted primary high hyperdiploid cells (~1500-fold), while thiopurine resistance was detected in IKZF1-deleted primary BCR-ABL1-like and non-BCR-ABL1-like B-other cells (~2.7-fold). The previously described risk stratification classifiers, i.e. IKZF1
Mesh-Begriff(e)	Adolescent ; B-Lymphocytes/metabolism ; Child ; Child, Preschool ; Cohort Studies ; DNA Copy Number Variations/genetics ; Drug Resistance ; Female ; Gene Dosage ; Genes, p16/physiology ; Humans ; Ikaros Transcription Factor/genetics ; Male ; Neoplasm Proteins/genetics ; PAX5 Transcription Factor/genetics ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/genetics ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics ; Prognosis ; Proto-Oncogene Proteins c-ets/genetics ; Repressor Proteins/genetics ; Retinoblastoma Binding Proteins/genetics ; Trans-Activators/genetics ; Ubiquitin-Protein Ligases/genetics ; ETS Translocation Variant 6 Protein
Chemische Substanzen	EBF1 protein, human ; IKZF1 protein, human ; Neoplasm Proteins ; PAX5 Transcription Factor ; PAX5 protein, human ; Proto-Oncogene Proteins c-ets ; RB1 protein, human ; Repressor Proteins ; Retinoblastoma Binding Proteins ; Trans-Activators ; BTG1 protein, human (146835-72-5) ; Ikaros Transcription Factor (148971-36-2) ; Ubiquitin-Protein Ligases (EC 2.3.2.27)
Sprache	Englisch
Erscheinungsdatum	2019-03-15
Erscheinungsland	England
Dokumenttyp	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2615211-3
ISSN	2045-2322 ; 2045-2322
ISSN (online)	2045-2322
ISSN	2045-2322
DOI	10.1038/s41598-019-41078-4
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: NUTM1

Hormann, Femke M / Hoogkamer, Alex Q / Beverloo, H Berna / Boeree, Aurélie / Dingjan, Ilse / Wattel, Moniek M / Stam, Ronald W / Escherich, Gabriele / Pieters, Rob / den Boer, Monique L / Boer, Judith M

Haematologica

2019 Band 104, Heft 10, Seite(n) e455–e459

Mesh-Begriff(e)	Child ; Chromosome Banding ; Chromosomes, Human ; Female ; Gene Expression Regulation, Leukemic ; Humans ; Male ; Neoplasm Proteins/biosynthesis ; Neoplasm Proteins/genetics ; Nuclear Proteins/biosynthesis ; Nuclear Proteins/genetics ; Oncogene Proteins, Fusion/biosynthesis ; Oncogene Proteins, Fusion/genetics ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/genetics ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/metabolism ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/metabolism ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology
Chemische Substanzen	NUTM1 protein, human ; Neoplasm Proteins ; Nuclear Proteins ; Oncogene Proteins, Fusion
Sprache	Englisch
Erscheinungsdatum	2019-03-14
Erscheinungsland	Italy
Dokumenttyp	Letter ; Research Support, Non-U.S. Gov't
ZDB-ID	2333-4
ISSN	1592-8721 ; 0017-6567 ; 0390-6078
ISSN (online)	1592-8721
ISSN	0017-6567 ; 0390-6078
DOI	10.3324/haematol.2018.206961
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Uh III Zs.76: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾
- Im ZB MED-Bestand
- Kostenpflichtig bestellen

Artikel ; Online: JAK2

Steeghs, Elisabeth M P / Jerchel, Isabel S / de Goffau-Nobel, Willemieke / Hoogkamer, Alex Q / Boer, Judith M / Boeree, Aurélie / van de Ven, Cesca / Koudijs, Marco J / Besselink, Nicolle J M / de Groot-Kruseman, Hester A / Zwaan, Christian Michel / Horstmann, Martin A / Pieters, Rob / den Boer, Monique L

Oncotarget

2017 Band 8, Heft 52, Seite(n) 89923–89938

Abstract: ... ...

Abstract	JAK2
Sprache	Englisch
Erscheinungsdatum	2017-10-27
Erscheinungsland	United States
Dokumenttyp	Journal Article
ZDB-ID	2560162-3
ISSN	1949-2553 ; 1949-2553
ISSN (online)	1949-2553
ISSN	1949-2553
DOI	10.18632/oncotarget.21027
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.

Boer, Judith M / Steeghs, Elisabeth M P / Marchante, João R M / Boeree, Aurélie / Beaudoin, James J / Beverloo, H Berna / Kuiper, Roland P / Escherich, Gabriele / van der Velden, Vincent H J / van der Schoot, C Ellen / de Groot-Kruseman, Hester A / Pieters, Rob / den Boer, Monique L

Oncotarget

2016 Band 8, Heft 3, Seite(n) 4618–4628

Abstract: Approximately 15% of pediatric B cell precursor acute lymphoblastic leukemia (BCP-ALL) is characterized by gene expression similar to that of BCR-ABL1-positive disease and unfavorable prognosis. This BCR-ABL1-like subtype shows a high frequency of B-cell ...

Abstract	Approximately 15% of pediatric B cell precursor acute lymphoblastic leukemia (BCP-ALL) is characterized by gene expression similar to that of BCR-ABL1-positive disease and unfavorable prognosis. This BCR-ABL1-like subtype shows a high frequency of B-cell development gene aberrations and tyrosine kinase-activating lesions. To evaluate the clinical significance of tyrosine kinase gene fusions in children with BCP-ALL, we studied the frequency of recently identified tyrosine kinase fusions, associated genetic features, and prognosis in a representative Dutch/German cohort. We identified 14 tyrosine kinase fusions among 77 BCR-ABL1-like cases (18%) and none among 76 non-BCR-ABL1-like B-other cases. Novel exon fusions were identified for RCSD1-ABL2 and TERF2-JAK2. JAK2 mutation was mutually exclusive with tyrosine kinase fusions and only occurred in cases with high CRLF2 expression. The non/late response rate and levels of minimal residual disease in the fusion-positive BCR-ABL1-like group were higher than in the non-BCR-ABL1-like B-others (p<0.01), and also higher, albeit not statistically significant, compared with the fusion-negative BCR-ABL1-like group. The 8-year cumulative incidence of relapse in the fusion-positive BCR-ABL1-like group (35%) was comparable with that in the fusion-negative BCR-ABL1-like group (35%), and worse than in the non-BCR-ABL1-like B-other group (17%, p=0.07). IKZF1 deletions, predominantly other than the dominant-negative isoform and full deletion, co-occurred with tyrosine kinase fusions. This study shows that tyrosine kinase fusion-positive cases are a high-risk subtype of BCP-ALL, which warrants further studies with specific kinase inhibitors to improve outcome.
Mesh-Begriff(e)	Adolescent ; Cohort Studies ; Female ; Fusion Proteins, bcr-abl/genetics ; Gene Deletion ; Germany ; Humans ; Ikaros Transcription Factor/genetics ; Intracellular Signaling Peptides and Proteins/genetics ; Janus Kinase 2/genetics ; Male ; Mutation ; Netherlands ; Oligonucleotide Array Sequence Analysis ; Oncogene Proteins, Fusion/genetics ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics ; Protein-Tyrosine Kinases/genetics ; Telomeric Repeat Binding Protein 2/genetics ; Young Adult
Chemische Substanzen	BCR-ABL1 fusion protein, human ; IKZF1 protein, human ; Intracellular Signaling Peptides and Proteins ; Oncogene Proteins, Fusion ; RCSD1 protein, human ; TERF2 protein, human ; Telomeric Repeat Binding Protein 2 ; Ikaros Transcription Factor (148971-36-2) ; ARG tyrosine kinase (EC 2.7.1.-) ; Protein-Tyrosine Kinases (EC 2.7.10.1) ; Fusion Proteins, bcr-abl (EC 2.7.10.2) ; JAK2 protein, human (EC 2.7.10.2) ; Janus Kinase 2 (EC 2.7.10.2)
Sprache	Englisch
Erscheinungsdatum	2016-11-28
Erscheinungsland	United States
Dokumenttyp	Journal Article
ZDB-ID	2560162-3
ISSN	1949-2553 ; 1949-2553
ISSN (online)	1949-2553
ISSN	1949-2553
DOI	10.18632/oncotarget.13492
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Details ▾
- Kostenpflichtig bestellen

Zum Seitenanfang

Zusatzmaterialien

Kategorien

Über subito bestellen

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Über subito bestellen

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Über subito bestellen

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Über subito bestellen

Zusatzmaterialien

Kategorien

Über subito bestellen